BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: ElRakaiby M, Dutilh BE, Rizkallah MR, Boleij A, Cole JN, Aziz RK. Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics. OMICS 2014;18:402-14. [PMID: 24785449 DOI: 10.1089/omi.2014.0018] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Le Bastard Q, Chevallier P, Montassier E. Gut microbiome in allogeneic hematopoietic stem cell transplantation and specific changes associated with acute graft vs host disease. World J Gastroenterol 2021; 27(45): 7792-7800 [PMID: 34963742 DOI: 10.3748/wjg.v27.i45.7792] [Reference Citation Analysis]
2 Özdemir V. OMICS 2.0: An Accelerator for Global Science, Systems Medicine and Responsible Innovation. OMICS 2015;19:579-80. [PMID: 26484977 DOI: 10.1089/omi.2015.0133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Schubert K, Olde Damink SWM, von Bergen M, Schaap FG. Interactions between bile salts, gut microbiota, and hepatic innate immunity. Immunol Rev. 2017;279:23-35. [PMID: 28856736 DOI: 10.1111/imr.12579] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
4 Abdollahi-Roodsaz S, Abramson SB, Scher JU. The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions. Nat Rev Rheumatol. 2016;12:446-455. [PMID: 27256713 DOI: 10.1038/nrrheum.2016.68] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 11.2] [Reference Citation Analysis]
5 Haldar S, Kapil A, Sood S, Sengupta S. Female reproductive tract microbiome in gynecological health and problems. Journal of Reproductive Health and Medicine 2016;2:S48-54. [DOI: 10.1016/j.jrhm.2016.11.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Dovrolis N, Kolios G, Spyrou GM, Maroulakou I. Computational profiling of the gut-brain axis: microflora dysbiosis insights to neurological disorders. Brief Bioinform 2019;20:825-41. [PMID: 29186317 DOI: 10.1093/bib/bbx154] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
7 Salah M, Azab M, Ramadan A, Hanora A. New Insights on Obesity and Diabetes from Gut Microbiome Alterations in Egyptian Adults. OMICS: A Journal of Integrative Biology 2019;23:477-85. [DOI: 10.1089/omi.2019.0063] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
8 Chen H, Gong J, Xing K, Liu M, Ren H, Luo J. Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment. Front Med 2022;8:742394. [DOI: 10.3389/fmed.2021.742394] [Reference Citation Analysis]
9 Khan FH, Bhat BA, Sheikh BA, Tariq L, Padmanabhan R, Verma JP, Shukla AC, Dowlati A, Abbas A. Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy. Semin Cancer Biol 2021:S1044-579X(21)00199-1. [PMID: 34273520 DOI: 10.1016/j.semcancer.2021.07.005] [Reference Citation Analysis]
10 Zeidán-Chuliá F, Gürsoy M, Neves de Oliveira BH, Özdemir V, Könönen E, Gürsoy UK. A Systems Biology Approach to Reveal Putative Host-Derived Biomarkers of Periodontitis by Network Topology Characterization of MMP-REDOX/NO and Apoptosis Integrated Pathways. Front Cell Infect Microbiol 2015;5:102. [PMID: 26793622 DOI: 10.3389/fcimb.2015.00102] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
11 Abdelsalam NA, Ramadan AT, ElRakaiby MT, Aziz RK. Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics. Front Pharmacol 2020;11:390. [PMID: 32372951 DOI: 10.3389/fphar.2020.00390] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
12 García S, Martínez-Cengotitabengoa M, López-Zurbano S, Zorrilla I, López P, Vieta E, González-Pinto A. Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review. J Clin Psychopharmacol 2016;36:355-71. [PMID: 27307187 DOI: 10.1097/JCP.0000000000000523] [Cited by in Crossref: 136] [Cited by in F6Publishing: 53] [Article Influence: 27.2] [Reference Citation Analysis]
13 Özdemir V, Kolker E. Precision Nutrition 4.0: A Big Data and Ethics Foresight Analysis—Convergence of Agrigenomics, Nutrigenomics, Nutriproteomics, and Nutrimetabolomics. OMICS: A Journal of Integrative Biology 2016;20:69-75. [DOI: 10.1089/omi.2015.0193] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
14 Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome 2018;6:92. [PMID: 29789015 DOI: 10.1186/s40168-018-0483-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Vitorino M, Baptista de Almeida S, Alpuim Costa D, Faria A, Calhau C, Azambuja Braga S. Human Microbiota and Immunotherapy in Breast Cancer - A Review of Recent Developments. Front Oncol 2022;11:815772. [DOI: 10.3389/fonc.2021.815772] [Reference Citation Analysis]
16 Kuntz TM, Gilbert JA. Introducing the Microbiome into Precision Medicine. Trends in Pharmacological Sciences 2017;38:81-91. [DOI: 10.1016/j.tips.2016.10.001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 10.8] [Reference Citation Analysis]
17 Evans J, Swart M, Soko N, Wonkam A, Huzair F, Dandara C. A Global Health Diagnostic for Personalized Medicine in Resource-Constrained World Settings: A Simple PCR-RFLP Method for Genotyping CYP2B6 g.15582C>T and Science and Policy Relevance for Optimal Use of Antiretroviral Drug Efavirenz. OMICS 2015;19:332-8. [PMID: 26415139 DOI: 10.1089/omi.2015.0039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
18 Sharma A, Buschmann MM, Gilbert JA. Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response? Clin Pharmacol Ther 2019;106:317-28. [PMID: 30937887 DOI: 10.1002/cpt.1437] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
19 Aly AM, Adel A, El-Gendy AO, Essam TM, Aziz RK. Gut microbiome alterations in patients with stage 4 hepatitis C. Gut Pathog 2016;8:42. [PMID: 27625705 DOI: 10.1186/s13099-016-0124-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 9.5] [Reference Citation Analysis]
20 Sublette ME, Cheung S, Lieberman E, Hu S, Mann JJ, Uhlemann AC, Miller JM. Bipolar disorder and the gut microbiome: A systematic review. Bipolar Disord 2021. [PMID: 33512753 DOI: 10.1111/bdi.13049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
21 Cussotto S, Walsh J, Golubeva AV, Zhdanov AV, Strain CR, Fouhy F, Stanton C, Dinan TG, Hyland NP, Clarke G, Cryan JF, Griffin BT. The gut microbiome influences the bioavailability of olanzapine in rats. EBioMedicine 2021;66:103307. [PMID: 33819741 DOI: 10.1016/j.ebiom.2021.103307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Turner RM, Park BK, Pirmohamed M. Parsing interindividual drug variability: an emerging role for systems pharmacology. Wiley Interdiscip Rev Syst Biol Med 2015;7:221-41. [PMID: 25950758 DOI: 10.1002/wsbm.1302] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
23 Hekmatshoar Y, Rahbar Saadat Y, Hosseiniyan Khatibi SM, Ozkan T, Zununi Vahed F, Nariman-Saleh-Fam Z, Pourghassem Gargari B, Sunguroglu A, Zununi Vahed S. The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental? Life Sci 2019;233:116680. [PMID: 31344431 DOI: 10.1016/j.lfs.2019.116680] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
24 Kambouris ME, Pavlidis C, Skoufas E, Arabatzis M, Kantzanou M, Velegraki A, Patrinos GP. Culturomics: A New Kid on the Block of OMICS to Enable Personalized Medicine. OMICS. 2018;22:108-118. [PMID: 28402209 DOI: 10.1089/omi.2017.0017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
25 Zinyama-Gutsire RB, Christiansen M, Hedley PL, Rusakaniko S, Hagen C, Stray-Pedersen B, Buzdugan R, Cowan F, Chasela C. HIV-1 Vertical Transmission in Zimbabwe in 622 Mother and Infant Pairs: Rethinking the Contribution of Mannose Binding Lectin Deficiency in Africa. OMICS 2016;20:433-41. [PMID: 27315016 DOI: 10.1089/omi.2016.0056] [Reference Citation Analysis]
26 Sahly N, Moustafa A, Zaghloul M, Salem TZ. Effect of radiotherapy on the gut microbiome in pediatric cancer patients: a pilot study. PeerJ 2019;7:e7683. [PMID: 31579590 DOI: 10.7717/peerj.7683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
27 Aziz RK, Hegazy SM, Yasser R, Rizkallah MR, ElRakaiby MT. Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions. Expert Opin Drug Metab Toxicol 2018;14:1043-55. [PMID: 30269615 DOI: 10.1080/17425255.2018.1530216] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
28 Hassan R, Allali I, Agamah FE, Elsheikh SSM, Thomford NE, Dandara C, Chimusa ER. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine. Brief Bioinform 2021;22:bbaa292. [PMID: 33253350 DOI: 10.1093/bib/bbaa292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Sfera A, Osorio C, Diaz EL, Maguire G, Cummings M. The Other Obesity Epidemic-Of Drugs and Bugs. Front Endocrinol (Lausanne) 2020;11:488. [PMID: 32849279 DOI: 10.3389/fendo.2020.00488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome 2018;6:92. [PMID: 29789015 DOI: 10.1186/s40168-018-0483-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 19.8] [Reference Citation Analysis]
31 Klatt NR, Cheu R, Birse K, Zevin AS, Perner M, Noël-romas L, Grobler A, Westmacott G, Xie IY, Butler J, Mansoor L, Mckinnon LR, Passmore JS, Abdool Karim Q, Abdool Karim SS, Burgener AD. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science 2017;356:938-45. [DOI: 10.1126/science.aai9383] [Cited by in Crossref: 218] [Cited by in F6Publishing: 201] [Article Influence: 43.6] [Reference Citation Analysis]
32 Fuentes‐chust C, Parolo C, Rosati G, Rivas L, Perez‐toralla K, Simon S, Lecuona I, Junot C, Trebicka J, Merkoçi A. The Microbiome Meets Nanotechnology: Opportunities and Challenges in Developing New Diagnostic Devices. Adv Mater 2021;33:2006104. [DOI: 10.1002/adma.202006104] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Zahran SA, Ali-Tammam M, Hashem AM, Aziz RK, Ali AE. Azoreductase activity of dye-decolorizing bacteria isolated from the human gut microbiota. Sci Rep 2019;9:5508. [PMID: 30940826 DOI: 10.1038/s41598-019-41894-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
34 Tsilimigras MC, Fodor A, Jobin C. Carcinogenesis and therapeutics: The microbiota perspective. Nat Microbiol. 2017;2:17008. [PMID: 28225000 DOI: 10.1038/nmicrobiol.2017.8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 12.4] [Reference Citation Analysis]
35 Rouanet A, Bolca S, Bru A, Claes I, Cvejic H, Girgis H, Harper A, Lavergne SN, Mathys S, Pane M, Pot B, Shortt C, Alkema W, Bezulowsky C, Blanquet-Diot S, Chassard C, Claus SP, Hadida B, Hemmingsen C, Jeune C, Lindman B, Midzi G, Mogna L, Movitz C, Nasir N, Oberreither M, Seegers JFML, Sterkman L, Valo A, Vieville F, Cordaillat-Simmons M. Live Biotherapeutic Products, A Road Map for Safety Assessment. Front Med (Lausanne) 2020;7:237. [PMID: 32637416 DOI: 10.3389/fmed.2020.00237] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
36 Pinto-Cardoso S, Klatt NR, Reyes-Terán G. Impact of antiretroviral drugs on the microbiome: unknown answers to important questions. Curr Opin HIV AIDS 2018;13:53-60. [PMID: 29028667 DOI: 10.1097/COH.0000000000000428] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
37 Potgieter M, Bester J, Kell DB, Pretorius E. The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol Rev 2015;39:567-91. [PMID: 25940667 DOI: 10.1093/femsre/fuv013] [Cited by in Crossref: 215] [Cited by in F6Publishing: 197] [Article Influence: 30.7] [Reference Citation Analysis]
38 Liu J, Liu C, Yue J. Radiotherapy and the gut microbiome: facts and fiction. Radiat Oncol 2021;16:9. [PMID: 33436010 DOI: 10.1186/s13014-020-01735-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
39 Özdemir V. New Biology and United Nations Sustainable Development Goals (SDGs) 2016–2030: Values Steering the OMICS: A Journal of Integrative Biology Editorial Flight Deck. OMICS: A Journal of Integrative Biology 2015;19:369-71. [DOI: 10.1089/omi.2015.0066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
40 Huang W, Zhang W. Pharmacomicrobiomics. In: Cai W, Liu Z, Miao L, Xiang X, editors. Pharmacogenomics in Precision Medicine. Singapore: Springer; 2020. pp. 181-99. [DOI: 10.1007/978-981-15-3895-7_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Tuteja S, Ferguson JF. Gut Microbiome and Response to Cardiovascular Drugs. Circ Genom Precis Med 2019;12:421-9. [PMID: 31462078 DOI: 10.1161/CIRCGEN.119.002314] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
42 Khamisy-Farah R, Furstenau LB, Kong JD, Wu J, Bragazzi NL. Gynecology Meets Big Data in the Disruptive Innovation Medical Era: State-of-Art and Future Prospects. Int J Environ Res Public Health 2021;18:5058. [PMID: 34064710 DOI: 10.3390/ijerph18105058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Ortega MA, Alvarez-Mon MA, García-Montero C, Fraile-Martinez O, Guijarro LG, Lahera G, Monserrat J, Valls P, Mora F, Rodríguez-Jiménez R, Quintero J, Álvarez-Mon M. Gut Microbiota Metabolites in Major Depressive Disorder-Deep Insights into Their Pathophysiological Role and Potential Translational Applications. Metabolites 2022;12:50. [PMID: 35050172 DOI: 10.3390/metabo12010050] [Reference Citation Analysis]
44 Sintim HO, Gürsoy UK. Biofilms as "Connectors" for Oral and Systems Medicine: A New Opportunity for Biomarkers, Molecular Targets, and Bacterial Eradication. OMICS 2016;20:3-11. [PMID: 26583256 DOI: 10.1089/omi.2015.0146] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
45 Dove ES, Barlas IÖ, Birch K, Boehme C, Borda-Rodriguez A, Byne WM, Chaverneff F, Coşkun Y, Dahl ML, Dereli T, Diwakar S, Elbeyli L, Endrenyi L, Eroğlu-Kesim B, Ferguson LR, Güngör K, Gürsoy U, Hekim N, Huzair F, Kaushik K, Kickbusch I, Kıroğlu O, Kolker E, Könönen E, Lin B, Llerena A, Malhan F, Nair B, Patrinos GP, Şardaş S, Sert Ö, Srivastava S, Steuten LM, Toraman C, Vayena E, Wang W, Warnich L, Özdemir V. An Appeal to the Global Health Community for a Tripartite Innovation: An "Essential Diagnostics List," "Health in All Policies," and "See-Through 21(st) Century Science and Ethics". OMICS 2015;19:435-42. [PMID: 26161545 DOI: 10.1089/omi.2015.0075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
46 Long JE, Jankovic M, Maddalo D. Drug discovery oncology in a mouse: concepts, models and limitations. Future Sci OA 2021;7:FSO737. [PMID: 34295539 DOI: 10.2144/fsoa-2021-0019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Gilbert JA, Quinn RA, Debelius J, Xu ZZ, Morton J, Garg N, Jansson JK, Dorrestein PC, Knight R. Microbiome-wide association studies link dynamic microbial consortia to disease. Nature. 2016;535:94-103. [PMID: 27383984 DOI: 10.1038/nature18850] [Cited by in Crossref: 388] [Cited by in F6Publishing: 315] [Article Influence: 64.7] [Reference Citation Analysis]
48 Bakshi HA, Quinn GA, Aljabali AAA, Hakkim FL, Farzand R, Nasef MM, Abuglela N, Ansari P, Mishra V, Serrano-Aroca Á, Tambuwala MM. Exploiting the Metabolism of the Gut Microbiome as a Vehicle for Targeted Drug Delivery to the Colon. Pharmaceuticals (Basel) 2021;14:1211. [PMID: 34959610 DOI: 10.3390/ph14121211] [Reference Citation Analysis]
49 Tuddenham S, Ghanem KG. A microbiome variable in the HIV-prevention equation. Science 2017;356:907-8. [PMID: 28572351 DOI: 10.1126/science.aan6103] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
50 Marcobal A, Yusufaly T, Higginbottom S, Snyder M, Sonnenburg JL, Mias GI. Metabolome progression during early gut microbial colonization of gnotobiotic mice. Sci Rep 2015;5:11589. [PMID: 26118551 DOI: 10.1038/srep11589] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
51 Ding C, Tang W, Fan X, Wu G. Intestinal microbiota: a novel perspective in colorectal cancer biotherapeutics. Onco Targets Ther 2018;11:4797-810. [PMID: 30147331 DOI: 10.2147/OTT.S170626] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 5.8] [Reference Citation Analysis]
52 Alpuim Costa D, Nobre JG, Batista MV, Ribeiro C, Calle C, Cortes A, Marhold M, Negreiros I, Borralho P, Brito M, Cortes J, Braga SA, Costa L. Human Microbiota and Breast Cancer-Is There Any Relevant Link?-A Literature Review and New Horizons Toward Personalised Medicine. Front Microbiol 2021;12:584332. [PMID: 33716996 DOI: 10.3389/fmicb.2021.584332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Litman T. Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases. APMIS 2019;127:386-424. [PMID: 31124204 DOI: 10.1111/apm.12934] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
54 Bhat SA, Kaur R, Chauhan A, Pal A. The microbiome and precision oncology: an emerging paradigm in anticancer therapy. Crit Rev Microbiol 2022;:1-14. [PMID: 35164642 DOI: 10.1080/1040841X.2022.2035313] [Reference Citation Analysis]
55 Özdemir V, Arga KY, Aziz RK, Bayram M, Conley SN, Dandara C, Endrenyi L, Fisher E, Garvey CK, Hekim N, Kunej T, Şardaş S, Von Schomberg R, Yassin AS, Yılmaz G, Wang W. Digging Deeper into Precision/Personalized Medicine: Cracking the Sugar Code, the Third Alphabet of Life, and Sociomateriality of the Cell. OMICS 2020;24:62-80. [PMID: 32027574 DOI: 10.1089/omi.2019.0220] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
56 Mussap M, Loddo C, Fanni C, Fanos V. Metabolomics in pharmacology - a delve into the novel field of pharmacometabolomics. Expert Rev Clin Pharmacol 2020;13:115-34. [PMID: 31958027 DOI: 10.1080/17512433.2020.1713750] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
57 Sun YZ, Zhang DH, Cai SB, Ming Z, Li JQ, Chen X. MDAD: A Special Resource for Microbe-Drug Associations. Front Cell Infect Microbiol 2018;8:424. [PMID: 30581775 DOI: 10.3389/fcimb.2018.00424] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
58 Tralau T, Sowada J, Luch A. Insights on the human microbiome and its xenobiotic metabolism: what is known about its effects on human physiology? Expert Opin Drug Metab Toxicol 2015;11:411-25. [PMID: 25476418 DOI: 10.1517/17425255.2015.990437] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
59 Sharma AK, Jaiswal SK, Chaudhary N, Sharma VK. A novel approach for the prediction of species-specific biotransformation of xenobiotic/drug molecules by the human gut microbiota. Sci Rep 2017;7:9751. [PMID: 28852076 DOI: 10.1038/s41598-017-10203-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
60 Mehmood K, Moin A, Hussain T, Rizvi SMD, Gowda DV, Shakil S, Kamal MA. Can manipulation of gut microbiota really be transformed into an intervention strategy for cardiovascular disease management? Folia Microbiol (Praha) 2021;66:897-916. [PMID: 34699042 DOI: 10.1007/s12223-021-00926-5] [Reference Citation Analysis]
61 Gately S. Human Microbiota and Personalized Cancer Treatments: Role of Commensal Microbes in Treatment Outcomes for Cancer Patients. In: Von Hoff DD, Han H, editors. Precision Medicine in Cancer Therapy. Cham: Springer International Publishing; 2019. pp. 253-64. [DOI: 10.1007/978-3-030-16391-4_10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
62 Zinyama-Gutsire RB, Chasela C, Kallestrup P, Rusakaniko S, Christiansen M, Ngara B, Gomo E, Ullum H, Erikstrup C, Madsen HO, Stray-Pedersen B, Garred P, Mduluza T. HIV-1 Disease Progression and Survival in an Adult Population in Zimbabwe: Is There an Effect of the Mannose Binding Lectin Deficiency? OMICS 2015;19:542-52. [PMID: 26348711 DOI: 10.1089/omi.2015.0047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
63 Anand A, Sharma K, Chen W, Sharma NK. Using current data to define new approach in age related macular degeneration: need to accelerate translational research. Curr Genomics 2014;15:266-77. [PMID: 25132797 DOI: 10.2174/1389202915666140516204512] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
64 Guthrie L, Kelly L. Bringing microbiome-drug interaction research into the clinic. EBioMedicine 2019;44:708-15. [PMID: 31151933 DOI: 10.1016/j.ebiom.2019.05.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
65 Ostrov BE, Amsterdam D. Immunomodulatory interplay of the microbiome and therapy of rheumatic diseases. Immunol Invest 2017;46:769-92. [PMID: 29058546 DOI: 10.1080/08820139.2017.1373828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
66 Naqvi S, Asar TO, Kumar V, Al-Abbasi FA, Alhayyani S, Kamal MA, Anwar F. A cross-talk between gut microbiome, salt and hypertension. Biomed Pharmacother 2021;134:111156. [PMID: 33401080 DOI: 10.1016/j.biopha.2020.111156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
67 Clarke G, Sandhu KV, Griffin BT, Dinan TG, Cryan JF, Hyland NP, France CP. Gut Reactions: Breaking Down Xenobiotic–Microbiome Interactions. Pharmacol Rev 2019;71:198-224. [DOI: 10.1124/pr.118.015768] [Cited by in Crossref: 101] [Cited by in F6Publishing: 85] [Article Influence: 33.7] [Reference Citation Analysis]
68 Chen X, Guan NN, Sun YZ, Li JQ, Qu J. MicroRNA-small molecule association identification: from experimental results to computational models. Brief Bioinform 2018. [PMID: 30325405 DOI: 10.1093/bib/bby098] [Cited by in Crossref: 31] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
69 Curini L, Amedei A. Cardiovascular Diseases and Pharmacomicrobiomics: A Perspective on Possible Treatment Relevance. Biomedicines 2021;9:1338. [PMID: 34680455 DOI: 10.3390/biomedicines9101338] [Reference Citation Analysis]
70 Brusselaers N. Prescribed Drugs and the Microbiome. Gastroenterol Clin North Am 2019;48:331-42. [PMID: 31383274 DOI: 10.1016/j.gtc.2019.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
71 Lach G, Schellekens H, Dinan TG, Cryan JF. Anxiety, Depression, and the Microbiome: A Role for Gut Peptides. Neurotherapeutics. 2018;15:36-59. [PMID: 29134359 DOI: 10.1007/s13311-017-0585-0] [Cited by in Crossref: 170] [Cited by in F6Publishing: 146] [Article Influence: 56.7] [Reference Citation Analysis]
72 Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome 2018;6:92. [PMID: 29789015 DOI: 10.1186/s40168-018-0483-7] [Reference Citation Analysis]
73 Sarkar A, Lehto SM, Harty S, Dinan TG, Cryan JF, Burnet PWJ. Psychobiotics and the Manipulation of Bacteria-Gut-Brain Signals. Trends Neurosci. 2016;39:763-781. [PMID: 27793434 DOI: 10.1016/j.tins.2016.09.002] [Cited by in Crossref: 319] [Cited by in F6Publishing: 263] [Article Influence: 53.2] [Reference Citation Analysis]
74 Hatton GB, Madla CM, Rabbie SC, Basit AW. All disease begins in the gut: Influence of gastrointestinal disorders and surgery on oral drug performance. Int J Pharm 2018;548:408-22. [PMID: 29969711 DOI: 10.1016/j.ijpharm.2018.06.054] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]